Are diabetes drugs the next profit growth point? Pharmaceutical companies are accelerating their efforts

【Pharmaceutical Network Market Analysis】Diabetes is one of the chronic diseases with high prevalence, and the demand for drugs is large
.

With the deepening of the aging of the population, the iterative upgrading of drug varieties and the influence of medical insurance policy orientation, China's diabetes drug market will also accelerate its expansion
.

According to the data, China's diabetes drug market has reached 63.
2 billion yuan in 2020, and it is expected that in 2022, this market size will be close to 86.
2 billion yuan
.

Are diabetes drugs the next profit growth point? (Image source: Pharmaceutical Network) The market demand for diabetes drugs is huge, which has also attracted many pharmaceutical companies to enter the market
.

Rudong Sunshine Medicine said that in order to resist the risks brought by the "one product" to the company, the company has begun to develop the diabetes drug market
.

According to the data, in order to further enrich the product line in the field of diabetes, Dongguang Pharmaceutical has also acquired a number of diabetes treatment drugs
from its related party Guangdong Dongguang Pharmaceutical.

It is reported that in the field of diabetes drugs, many domestic enterprises have increased innovation and achieved new breakthroughs
in the field of innovative drugs.

For example, the original innovative drug for diabetes treatment independently developed by Renhui Biology, benarutide, as a short-acting GLP-1 receptor agonist, is administered during meals, which is more suitable for the secretion of endogenous GLP-1, which can improve the function of islet β cells to a certain extent, promote premature insulin secretion, inhibit glucagon secretion, and act on peripheral tissues to improve insulin resistance
.

At the same time, benarutide can also delay gastric emptying, reduce liver glycogen output, reduce appetite, and reduce patients' postprandial blood sugar
.

In addition, HiSco recently announced that the company's innovative drug HSK7653 tablets have completed two phase III clinical trials, and the two trials have enrolled more than 900 patients with type 2 diabetes, and the test results have shown good clinical effects and reached a preset endpoint
.

HSK7653 tablets successfully approved for marketing will become a bi-weekly preparation of hypoglycemic drugs, its hypoglycemic effect is safe, effective and stable, and the frequency of taking the drug once a week can ensure better medication compliance, which will hopefully provide a better choice
for the treatment of patients with type 2 diabetes.

Norte Bio recently also said on the interactive platform that the company's innovative drug SPN0103-009 injection to be used to treat type 2 diabetes and obesity is a new, long-acting GLP-1 peptide analogue, and the company has obtained a clinical trial approval notice issued by the State Food and Drug Administration in July this year; GLP-1/GIP dual-target innovative drug SPN007, suitable for type 2 diabetes, obesity, NASH, the company has completed the laboratory evaluation of activity and efficacy and obtained a compound invention certificate
.

Recently, the CDE also showed that Xinlitai's new class 1 drug SAL0112 tablets have obtained tacit permission for clinical trials and are intended to be used for blood glucose control
in patients with type 2 diabetes.

It is understood that SAL0112 tablets are oral small molecule bias agonists of glucagon-like peptide-1 receptor (GLP-1R), which is an innovative drug independently developed by Xinlitai, and the indications to be developed include weight management
of type 2 diabetes mellitus (T2DM), adult obese patients or overweight patients.

GLP-1R agonists can be applied to type 2 diabetes and obesity, with cardiac and renal benefits
.

The industry said that with the increase in the number of patients, the increase in per capita disposable income, and the expansion of diabetes drug indications and other factors, in recent years, China's diabetes drug market has shown a growing trend
year by year.

Strengthening the research and development of diabetes drugs may become the next profit growth point
chased by some pharmaceutical companies.

Data show that there are currently 69 diabetes drug projects in China in research and development, of which 4 projects are preclinical
.

There are 38 R&D projects
from Clinical Phase 1 to Clinical Phase 3.

Among them, insulin is still a multi-target for research and development, with 25 preclinical projects
.

It is worth mentioning that although the diabetes drug market is growing rapidly, in the field of diabetes research and development, the number of domestic innovative drugs is not much
.

The industry said that the development trend of the diabetes drug market in the future is mainly manifested in the following aspects: the old varieties extend the life cycle through compound preparations; From Fast-follow to First-in-class; Diabetes management
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.